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INTRODUCTION
Mucinous adenocarcinoma (MAC) is morphologically defined as an adenocarcinoma in which more than half of the lesion composed of mucin. 1 They are found in many organs' carcinomas, such as carcinomas of the breast, pancreas, liver, gallbladder and digestive tract. The frequency of MACs in colorectal adenocarcinomas has been reported to be 5%-15%. [2] [3] [4] [5] Particularly in two genetic pathways for gastrointestinal carcinogenesis, the suppressor pathway and the mutator pathway. 7 The suppressor pathway is caused by inactivation of tumor suppressor genes (e.g. APC and p53) and activation of oncogenes (e.g. K-ras) and the tumors demonstrate chromosomal instability, whereas the mutator pathway, i.e. dysfunction of the DNA MMR system, is the profound abnormality that lead to the accumulation of nucleotide insertion/deletion mutation in the coding sequences of the target genes (e.g.
TGF-β type II receptor, IGF-II receptor and Bax)
8,9 and the tumors showing microsatellite instability (MSI). MSI has been described in many human tumors, especially in HNPCC. [10] [11] [12] [13] MSI is detected in about 15% of the colorectal cancers and is associated with diploid or near-diploid tumors and defective MMR machinery. Tumors with MSI are more likely to be right-sided with mucinous histology, poor differentiation and tumor-infiltrating lymphocytes.
14 To examine the possibility to subtype MACs of the colorectum, we conducted molecular pathological analyses to discriminate the two major genetic pathways and searched for their clinicopathological differences.
MATERIALS AND METHODS

Tissue samples and DNA extraction
A total of 35 MACs of the colorectum, surgically removed at the Kobe University
Hospital from May 1994 to April 2002, were studied. Informed consent for the scientific analysis of resected specimen was obtained from all patients. All resected specimens were fixed in 10% formalin and embedded in paraffin.
Clinicopathological information was obtained from medical charts and histopathological examination was performed according to the General Rules for
Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus. Selected blocks were sectioned into 4-µm-thick slices for DNA extraction and immunohistochemical analysis. For DNA extraction, after deparaffinization, the specimens were stained with hematoxylin and eosin. The tumor areas and corresponding non-neoplastic colorectal mucosa were scraped using a toothpick and placed in a microtube containing extraction buffer (20 µl Tris-HCl, pH8.5, 1 mM EDTA and 0.2 mg/ml proteinase K) and incubated at 55˚C overnight.
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Proteinase K was inactivated by boiling for 5 min after incubation.
Immunohistochemical analysis
Immunohistochemical analysis was carried out with monoclonal antibodies to p53 (DO-7, dilution 1:50; DaKoCytomation, Copenhagen, Denmark), hMLH1
(G168-728, dilution 1:100; BD Biosciences, San Diego, CA, USA), CD10 (56C6, dilution 1:100; Novocastra Laboratories, Newcastle-upon-Tyne, UK), MUC2
(Ccp58, dilution 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA), human gastric mucin (HGM) (45M1, dilution 1:50; Novocastra), M-GGMC-1 (HIK1083, dilution 1:50; Kanto Kagaku, Tokyo, Japan) and Ki-67 (MIB-1, dilution 1:100; Immunotech, Marseilles, France). Dewaxed and rehydrated specimens were microwaved (p53, CD10, MUC2, HGM and Ki-67) or autoclaved (hMLH1 and M-GGMC-1) in 0.01 M citrate buffer (pH 6.0) for antigen retrieval.
Endogenous peroxidase activity and nonspecific binding were blocked by 0.03% hydrogen peroxide in methanol and blocking reagent in LSAB2 Kit representative high-power fields.
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We divided the immunoreactivity of p53 and hMLH1 in cancer tissue into two groups: strong (grade of immunoreactivity was ++ or +++), or weak (+ or -). for 45 s) after the initial Taq DNA polymerase activation step (95˚C for 10 min), followed by a final extension for 10 min at 72˚C. PCR products were electrophoresed in ABI PRISM 310 Genetic Analyzer along with GeneScan-500
Microsatellite analysis
[ROX] molecular weight standard (Applied Biosystems). The size of the PCR product was analyzed using GeneScan software (Applied Biosystems). We classified the status of MSI in each tumor according to the criterion by Boland et al. 19 Microsatellite stable (MSS), MSI was not observed in any microsatellite locus examined; low frequency of MSI (MSI-L), one or two out of nine loci revealed MSI; high frequency of MSI (MSI-H), three or more microsatellite loci showed MSI. Alleles were defined as the two highest peaks (for example, tumor DNA alleles, T1, T2; normal DNA alleles, N1, N2) within the expected size range.
A ratio of (T1:T2/N1:N2) <0.67 or >1.50 was scored as a loss of heterozygosity (LOH).
PCR-single-strand conformation polymorphism and direct sequencing analysis
Exons five to eight, where most mutations of the p53 gene were found in human (SSCP) analysis of amplified exons were performed as a screening step before sequencing, with some modifications. 17 PCR products of p53 exons were separated by 20% polyacrylamide gels with 5% glycerol, and gels were stained and visualized with the Silver Staining Kit (ATTO, Osaka, Japan).
PCR products that showed a shifted band in PCR-SSCP analysis were amplified again using the same primers, separated in 2.5% low-melting-point agarose gel and purified by QIAquick Gel Extraction Kit (QIAGEN GmbH, Hilden, Germany). Resultant PCR products were sequenced using the ABI PRISM BigDye TM Terminator v3.0 Cycle Sequenced Ready Reaction (Applied Biosystems) and an automated DNA sequencer.
Subclassified types of MACs of the colorectum
According to the result of microsatellite analyses and p53 status, we subclassified these MACs of the colorectum into three subtypes: the mutator-type, the tumors with MSI-H; the suppressor/p53-type, the tumor with strong p53 expression, with p53 gene mutation or LOH at D17S250 (an adjacent locus to p53); the unclassified tumors, the other tumors.
Statistical analysis
Statistical comparisons were performed by the Fisher's PLSD test and the χ 2 for three independent groups. A P value less than 0.05 was regarded as statistically significant.
RESULTS
Subclassification of MACs of the colorectum
We first performed a microsatellite assay in tumors with nine microsatellite 
Expression of hMLH1 and epithelial mucin in MACs of the colorectum
The immunohistochemical level of hMLH1 expression (-, +, ++, +++) were detected in 15 (42.9%), 2 (5.7%), 14 (40%) and 4 (11.4%) of the 35 cases, respectively. All of the cases of mutator-type tumors showed loss of hMLH1 expression (Figs. 1,2C ). While 11 (78.6%) and 7 (50%) cases in the suppressor/p53-type and unclassified tumors, respectively, revealed strong expression of hMLH1 (Figs. 1,3C ). No significant correlation was detected between decreased expression of hMLH1 and clinicopathologic parameter (data not shown).
Next, immunohistochemical analyses of epithelial mucin types in these
MACs of the colorectum were performed ( Table 1) 
Ki-67 labeling index, lymphocytic infiltration and clinicopathological parameters in MAC of the colorectum
We also compared the proliferative activity of cancer cells among the MACs of the colorectum by Ki-67 labeling index (Fig. 4) . The average values of the Ki-67 labeling index in the mutator-type, the suppressor/p53-type and the unclassified tumors were 60.3%, 54.3% and 49.5%, respectively. There was no significant difference in the proliferative activity between the suppressor/p53-type and the mutator-type tumors.
Lymphocytic infiltration at the advancing front of the tumor was graded as marked, moderate and little or none ( Table 2 ). The marked and moderate lymphocytic infiltration was observed in 7 (100%), 5 (35.7 %) and 8 (57.1%) cases in the mutator-type, the suppressor/p53-type and unclassified tumors, respectively. The mutator-type tumors showed significantly higher frequency of lymphocytic infiltration in comparison with the suppressor type (P = 0.005) or unclassified tumors (P = 0.040).
Finally, we compared the clinicopathological parameters among the mutator-type, suppressor/p53-type and unclassified tumors ( Table 3 ). The suppressor/p53-type tumors demonstrated significant association with distal colon location (P = 0.019), venous invasion (P = 0.002), extent of lymph node metastasis (P = 0.007) and higher tumor stage (P = 0.018). However, significant difference was not observed in other clinicopathological parameters including age, gender, tumor size, lymphatic invasion and depth of invasion.
DISCUSSION
In this study, we found 20% of colorectal MACs exhibited MSI-H, which was higher than the reported frequency of MSI-H in other types of colorectal carcinomas (10-15%). [20] [21] [22] function. However, Chiaravalli et al. 25 reported that the absence of immunostaining for hMLH1 was observed more frequently than that for hMSH2 in MSI-positive sporadic colorectal carcinomas (7.1-92.9%), suggesting that hMLH1 dysfunction might be the main reason for the induction of MSI in colorectal carcinoma. Further investigation will be required to clarify the role of abnormality of hMSH2 or other MMR genes in MACs of the colorectum as well as the status of hypermethylation of the hMLH1 gene promoter region. 26, 27 We subclassified the suppressor/p53-type tumors by the status of p53
and found that 40% of MACs demonstrated of p53 mutation, p53 nuclear accumulation or LOH at D17S250. Protein p53 accumulation has been detected in 24-72% colorectal carcinoma and mutation of p53 gene was found in approximately 50% of them. 28, 29 We detected p53 overexpression in 37%
(13/35) and p53 point mutation in 29% (10/35) cases. On the other hand, we could not detect p53 mutation, p53 nuclear accumulation or LOH at D17S250 in all the seven mutator-type tumors. This finding is in line with those from other studies.
30,31
MACs of the colorectum in the present study revealed similar biological and phenotypic characteristics of colorectal carcinoma in general developing through the mutator-type and the suppressor/p53-type pathways. 
Total 35 22 (63) 13 (37) 4 (11) 31 (89) 33 (94) 2 (6) 13 (37) 22 (63) Suppressor/p53 14 5 (36) 9 (64) 4 (29) 10 (71) 13 (93) 1 (7) 3 (21) 
